Answers are grounded in this paper and cite their sources.
This editorial summarizes key recent findings in the diagnosis, risk stratification, and management of acute coronary syndromes and cardiogenic shock.
Soluble biomarkers, in particular troponin, have revolutionized the management of acute coronary syndromes.1,2 While myocardial proteins reflect necrosis, so far no biomarkers reflect early events such as ongoing ischaemia.3 Furthermore, precise risk stratification at presentation and after the acute event is still not perfect.4 Roland Klingenberg and colleagues from the Kerckhoff Klinik in Bad Nauheim, Germany addressed this issue in their Fast Track ‘Cysteine-rich angiogenic inducer 61 (Cyr61):a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes’. They identified a novel biomarker, i.e. the cysteine-rich angiogenic inducer 61 or Cyr61, involved in the early events leading to acute coronary syndromes and evaluated its role in diagnosis and risk stratification.5 Its identification was based on gene expression profiling in coronary thrombi obtained from ST-segment elevation myocardial infarction patients where Cyr61 gene transcripts were highly up-regulated compared with peripheral mononuclear cells. In a murine ischaemia–reperfusion model, myocardial Cyr61 expression was markedly increased compared with controls. Similarly, Cyr61 was rapidly released after occlusion of a septal branch in hypertrophic obstructive cardiomyopathy. In >2100 patients, Cyr61 improved risk stratification for all-cause mortality when added to the reference GRACE risk score at 30 days and 1 year, surpassing high-sensitivity troponin T. The authors conclude that Cyr61 is a novel early biomarker reflecting myocardial injury that improves risk stratification in acute coronary syndromes. Microvascular obstruction is the underlying cause for the no-reflow phenomenon in ST-segment elevation myocardial infarction6 and so far difficult to treat.7 Although microvascular obstruction can be assessed by cardiac magnetic resonance imaging,8 its relationship to prognosis has not been convincingly demonstrated. In their manuscript entitled ‘Relationship between microvascular obstruction and adverse events followingprimary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis fromsevenrandomizedtrials’, Gregg W. Stone and colleagues from the Columbia University Medical Center in New York City sought to determine the relationship between microvascular obstruction assessed early after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction and all-cause mortality, hospitalization for heart failure, and reinfarction.9 They performed a pooled analysis using 1688 patients from seven randomized primary percutaneous coronary intervention trials in which microvascular obstruction was assessed after reperfusion by cardiac magnetic resonance imaging using late gadolinium enhancement. Microvascular obstruction was present in 57% of patients, and median microvascular obstruction averaged 0.47% of left ventricular myocardial mass. A graded response was present between the extent of microvascular obstruction and subsequent mortality and hospitalization for heart failure. Microvascular obstruction remained significantly associated with all-cause mortality, but not with subsequent myocardial infarction even after further adjustment for infarct size. The authors conclude that the presence and extent of microvascular obstruction measured by cardiac magnetic resonance imaging after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction is strongly associated with mortality and hospitalization for heart failure within the first year (Figure 1). These novel findings are further discussed in an interesting Editorial by Robert A. Kloner from the Huntington Medical Research Institutes in Pasadena, California.10 Time-to-first event analysis (from time of study entry) according to tertiles of MVO for the composite endpoint of all-cause mortality or heart failure hospitalization (from de Waha S, Patel MR, Granger CB, Magnus Ohman E, Maehara A, Eitel I, Ben-Yehuda O, Jenkins P, Thiele H, Stone GW. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. See pages 3502–3510). Myocardial infarction has been categorized into five types.11 The differentiation of type 1 infarction due to plaque rupture and type 2 infarction due to an imbalance of supply and demand in the context of hypotension, tachycardia, or bleeding is important, but challenging in the emergency department. In their article entitled ‘Discrimination of patients with type 2 myocardial infarction’, Johannes Tobias Neumann and colleagues from the University Heart Center Hamburg in Germany aimed to investigate the clinical characteristics and cardiovascular outcome of type 2 myocardial infarction and to develop a clinical decision tool to differentiate type 1 from type 2 myocardial infarction.12 Type 2 myocardial infarction was the final diagnosis of 99 of 1548 prospectively enrolled patients. Such patients showed a high 1-year mortality rate of 14%, which more than equalled that of type 1 myocardial infarction (9.4%). Female sex, not having radiating chest pain, and a baseline high-sensitivity troponin I concentration ≤40.8 ng/L were the strongest predictors for type 2 myocardial infarction. Their combination resulted in an area under the curve of 0.71 to discriminate type 1 from type 2 myocardial infarction. The binary score based on this model assigned one point to each of the predictors. Patients with the highest score value of 3 had a 72% probability of type 2 myocardial infarction (Figure 2). Thus, patients with type 2 myocardial infarction are a heterogeneous population with high cardiovascular risk. A score based on laboratory and clinical parameters might help to differentiate it from type 2 myocardial infarction. This clinical value of these findings is critically discussed in an Editorial by Kristian Thygesen from the Aarhus University Hospital in Denmark.13 Performance and characteristics of the diagnostic model to predict the probability of T2MI. Score based on the most important predictors from the multivariable model and the related probability of T2MI (from Tobias Neumann J, Arne Sörensen N, Rübsamen N, Ojeda F, Renné T, Qaderi V, Teltrop E, Kramer S, Quantius L, Zeller T, Karakas M, Blankenberg S, Westermann D. Discrimination of patients with type 2 myocardial infarction. See pages 3514–3520). Cardiogenic shock is a severe complication of an acute myocardial infarction.14 Indeed, although mortality of infarction has been dramatically reduced over the last decades,15 shock remains a presentation with an exorbitant mortality.16 Evidence on the impact on clinical outcome of active mechanical circulatory support devices in cardiogenic shock is scarce. In a collaborative meta-analysis article entitled ‘Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis ofrandomizedtrials’, Holger Thiele and colleagues from the University of Leipzig–Heart Center in Germany investigated the efficacy and safety of percutaneous active mechanical circulatory support vs. standard care in cardiogenic shock.17 Randomized trials comparing percutaneous active mechanical circulatory support with controls in patients with cardiogenic shock were identified through searches of the medical literature. Four trials randomizing 148 patients to either TandemHeart™ or Impella® mechanical circulatory support vs. control were identified. There was no difference in 30-day mortality for active mechanical circulatory support compared with intra-aortic balloon pumping that served as control, although it significantly increased mean arterial pressure and decreased arterial lactate at a comparable cardiac index and pulmonary capillary wedge pressure. No significant difference was observed in the incidence of leg ischaemia, whereas the rate of bleeding was significantly increased in patients receiving mechanical circulatory support compared with intra-aortic balloon pumping, with a relative risk of 2.50. Thus, the unselected use of active mechanical circulatory support in patients with cardiogenic shock complicating myocardial infarction does not appear to be useful. These disappointing results are put into clinical context in an Editorial by Navin Kumar Kapur from Tufts Medical Center in Boston, Massachusetts (USA), and a second Editorial authored by Petr Widimsky from the Hospital Kralovske Vinohrady in Prague Czechia.18,19 In a final Current Opinion entitled ‘The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum’, Deepak L. Bhatt and colleagues from Harvard Medical School in Boston, Massachusetts20 remind us that dual antiplatelet therapy consisting of aspirin and a P2Y12 receptor antagonist is a fundamental component of acute coronary syndrome management, with longstanding endorsements by both the American College of Cardiology Foundation and American Heart Association21 and the European Society of Cardiology.22 Indeed, dual antiplatelet therapy reduces the risk of both stent thrombosis and spontaneous ischaemic events, at the cost of an increased bleeding risk.23,24 The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia poses a particular challenge for physicians, as they are at higher risk of both bleeding and, paradoxically, also ischaemic events. Unfortunately, there are currently no guideline recommendations or consensus reports to guide clinicians on the management of this cohort. In this setting, the authors examine the evidence to date and provide their opinion on future directions and management strategies for this group. The editors hope that readers of this issue of the European Heart Journal will find it of interest.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: